Document is current
Any future updates will be listed below
-
Authors
Oyama, Genko
Tomizawa, Yuji
Tsunemi, Taiji
Nojiri, Shuko
Hatano, Taku
Sako, Wataru
Hoshino, Yasunobu
Ueno, Shin-ichi
Kamiyama, Daiki
Oji, Yutaka
Okuzumi, Ayami
Taniguchi, Daisuke
Haginiwa, Haruna
Maeda, Takuma
Furusawa, Yoshihiko
Izutsu, Miwa
Hattori, Nobutaka
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 19 December 2025
First Online: 9 February 2026
Declarations
:
: G.O. has received honoraria from AbbVie, Abbott, Boston Scientific, Eisai Co. Ltd., FP Pharmaceutical Corporation, Kyowa Hakko Kirin, Medtronic, Ono Pharmaceutical Co. Ltd, Sumitomo Pharma, Takeda Pharmaceuticals Co. Ltd., and Viatris. T.M. has received consulting fees from Takeda Pharmaceuticals Co. Ltd. Y.F. and M.I. are employees of Takeda Pharmaceutical Co. Ltd. Y.T., T.T., S.N., T.H., W.S., Y.H., S.U., D.K., Y.O., A.O., D.T., H.H. have no conflicts to declare. N.H. has received consulting fees from AbbVie Inc., Eisai Co. Ltd., FP Pharmaceutical Corporation, Kyowa Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., and Sumitomo Pharma Co. Ltd.; lecture fees from Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., FP Pharmaceutical Corporation, Kyowa Kirin Co. Ltd., Nihon Medi-Physics Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; honoraria from AbbVie Inc., FP Pharmaceutical Corporation, Kyowa Kirin Co. Ltd., and Novartis Pharma K.K.; and grants from Boston Scientific Corporation, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Medtronic Japan Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., and Takeda Pharmaceutical Co. Ltd.
